Experts Highlight ‘Treat-and-Extend’ Approach as Key Strategy in Sustained Drug Delivery at COPHy 2026

Experts Highlight ‘Treat-and-Extend’ Approach as Key Strategy in Sustained Drug Delivery at COPHy 2026

Leading ophthalmology experts at the Controversies in Ophthalmology (COPHy) 2026 conference emphasized the growing importance of the “treat-and-extend” approach in combination with sustained drug delivery systems to improve patient outcomes in retinal diseases, as discussions at the meeting focused on evolving treatment strategies and long-term disease management.

The conference, held in March 2026, brought together global specialists to evaluate advancements in retinal therapies, particularly for conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts highlighted how integrating innovative drug delivery technologies with flexible treatment regimens could reduce patient burden while maintaining clinical effectiveness.

Shift Toward Personalized Treatment Strategies

Speakers at the event underscored a growing shift toward individualized treatment plans in ophthalmology. The treat-and-extend approach, which involves gradually increasing the interval between treatments based on patient response, has gained traction as a way to balance efficacy with convenience.

Clinicians noted that this strategy allows for tailored care, minimizing unnecessary injections while ensuring that disease activity remains controlled. The approach is particularly valuable in chronic retinal conditions that require long-term management.

Experts said that personalization is becoming increasingly important as patient populations age and demand for retinal care continues to rise globally.

Role of Sustained Drug Delivery Systems

Advances in sustained drug delivery were a central focus of discussions at COPHy 2026. These systems are designed to release medication over extended periods, reducing the need for frequent intravitreal injections.

Researchers highlighted several emerging technologies, including implantable devices and long-acting formulations, which aim to maintain therapeutic drug levels in the eye for months rather than weeks. Such innovations could significantly reduce treatment burden for both patients and healthcare providers.

The combination of sustained delivery and treat-and-extend regimens is seen as a promising strategy for optimizing long-term outcomes.

Improving Patient Adherence and Outcomes

One of the key challenges in managing retinal diseases is ensuring patient adherence to treatment schedules. Frequent clinic visits and injections can lead to treatment fatigue, resulting in missed appointments and suboptimal outcomes.

Experts at the conference noted that reducing treatment frequency through sustained delivery systems and flexible dosing intervals could improve adherence. Better adherence, in turn, is associated with improved visual outcomes and quality of life for patients.

Clinicians emphasized that simplifying treatment regimens is critical for addressing real-world challenges in ophthalmic care.

Balancing Efficacy and Treatment Burden

The discussions highlighted the need to strike a balance between maintaining treatment efficacy and reducing the burden on patients. While frequent dosing may offer optimal disease control, it is not always practical in routine clinical settings.

The treat-and-extend approach allows physicians to adjust treatment intervals based on disease stability, offering a compromise between fixed dosing and reactive treatment strategies. Experts noted that this flexibility is key to long-term disease management.

Emerging drug delivery technologies are expected to further enhance this balance by providing consistent therapeutic effects over extended periods.

Advances in Anti-VEGF Therapies

Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the cornerstone of treatment for many retinal diseases. At COPHy 2026, experts reviewed the latest developments in this class of drugs, including longer-acting formulations and novel delivery mechanisms.

These advancements are aimed at reducing injection frequency while maintaining or improving efficacy. Researchers highlighted ongoing clinical trials evaluating new agents and delivery platforms that could reshape treatment paradigms.

The integration of these innovations into clinical practice is expected to support more sustainable treatment approaches.

Clinical Evidence and Real-World Data

Presentations at the conference included both clinical trial results and real-world data, offering insights into how new strategies perform outside controlled study environments. Experts emphasized that real-world evidence is essential for understanding the practical benefits and limitations of emerging therapies.

Data presented suggested that combining treat-and-extend regimens with sustained drug delivery can achieve comparable outcomes to more intensive treatment schedules, with fewer interventions.

However, speakers also noted the importance of ongoing monitoring to ensure disease stability.

Challenges in Implementation

Despite the promise of new approaches, challenges remain in implementing them widely. These include cost considerations, access to advanced therapies, and the need for clinician training.

Healthcare systems may also need to adapt to accommodate new treatment models, including changes in reimbursement structures and clinical workflows. Experts stressed that successful adoption will require collaboration across stakeholders.

Addressing these challenges is seen as critical for maximizing the benefits of innovation in ophthalmology.

Future Directions in Retinal Care

Looking ahead, researchers and clinicians expect continued progress in drug delivery technologies and treatment strategies. The focus is likely to remain on reducing treatment burden while improving outcomes through precision medicine approaches.

Emerging areas of interest include gene therapies, combination treatments, and advanced imaging techniques that enable earlier detection and monitoring of disease activity.

Experts at COPHy 2026 emphasized that innovation will be key to meeting the growing demand for retinal care worldwide.

Global Impact on Ophthalmology Practice

The discussions at the conference reflect broader trends in ophthalmology, where the emphasis is shifting toward long-term disease management and patient-centered care. The adoption of flexible treatment strategies and advanced drug delivery systems is expected to transform clinical practice.

Clinicians highlighted the importance of adapting treatment approaches to local healthcare contexts, ensuring that innovations are accessible and effective across diverse settings.

The global exchange of knowledge at events like COPHy plays a vital role in advancing the field.

Conclusion

Experts at COPHy 2026 concluded that the integration of treat-and-extend strategies with sustained drug delivery systems represents a significant step forward in retinal disease management, offering the potential to improve outcomes while reducing the burden on patients and healthcare systems.